Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Gastrointestinal Therapeutics Market 2016-2020: Key Vendors are AbbVie, Johnson & Johnson, Takeda, Allergan & UCB - Research and Markets

Research and Markets
Posted on: 07 Nov 16

Research and Markets has announced the addition of the "Global Gastrointestinal Therapeutics Market 2016-2020" report to their offering.

The global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).

According to the report, increasing consumption of biologics will be a key driver for market growth. Biologics, available as either intravenous or subcutaneous injections, are increasingly becoming the treatment of choice for IBD. These therapeutics act by either blocking the interleukins or the TNF-a. HUMIRA (adalimumab), Remicade (infliximab), Simponi (golimumab), and Cimzia (Certolizumab pegol) are some anti-TNF agents, and Tysabri (natalizumab) and ENTYVIO (vedolizumab) are some anti-integrin agents available in the market for the treatment of ulcerative colitis and Crohn's disease. Apart from the already approved drugs, many biologics are still under development for the treatment of IBD.

Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota.

Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn's disease, ulcerative colitis, and peptic ulcers.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Takeda
  • Allergan
  • UCB

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Pipeline portfolio

Part 06: Market landscape

Part 07: Market segmentation by disease type

Part 08: Global IBD therapeutics market

Part 09: Global IBS therapeutics market

Part 10: Global gastrointestinal OTC drugs market

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.